Catalyst Pharmaceuticals, Inc.

NASDAQ
CPRX
Stock
Yield per half year: +9.62%
Dividend yield: 0%
Sector: Healthcare

Share chart Catalyst Pharmaceuticals, Inc.

Extended chart Simple chart
Financial Markets by TradingView

About Catalyst Pharmaceuticals, Inc.

Catalyst Pharmaceuticals, Inc., коммерческая биофармацевтическая компания, занимается разработкой и коммерциализацией методов лечения людей с редкими инвалидизирующими, хроническими нервно-мышечными и неврологическими заболеваниями в Соединенных Штатах. Он предлагает Firdapse, таблетки фосфата амифампридина для лечения пациентов с миастеническим синдромом Ламберта-Итона (LEMS); и Ruzurgi для лечения педиатрических пациентов с LEMS. Компания разрабатывает Firdapse для лечения миастении с положительной реакцией на антитела к MuSK и типа спинальной мышечной атрофии.

more details
Имеет лицензионные соглашения с BioMarin Pharmaceutical Inc.; и сотрудничество и лицензионное соглашение с Endo Ventures Limited для разработки и коммерциализации таблеток-дженериков Sabril. Компания Catalyst Pharmaceuticals, Inc. была основана в 2002 году и базируется в Корал-Гейблс, Флорида.
Add to compare list
Add to watchlist
Add to portfolio
Add to notification price

Main settings

IPO date 2006-11-08
ISIN US14888U1016
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт link
Цена ао 24.49
Change price per day: 0% (24.49)
Change price per week: -0.7699% (24.68)
Change price per month: +4.43% (23.45)
Change price per 3 month: +17.74% (20.8)
Change price per half year: +9.62% (22.34)
Change price per year: +47.8% (16.57)
Change price per 3 year: +255.96% (6.88)
Change price per 5 year: +432.39% (4.6)
Change price per 10 year: +547.88% (3.78)
Change price per year to date: +13.27% (21.62)
All parameters

Grade

Underestimation
Title Value Grade
P/S 5.3 2
P/BV 3.58 5
P/E 15.91 7
EV/EBITDA 8.99 8
Total: 7.5
Efficiency
Title Value Grade
ROA, % 24.8 7
ROE, % 29.38 8
Total: 7
Dividends
Title Value Grade
Div yield, % 0 0
DSI 0 0
Total: 0
Debt
Title Value Grade
Debt/EBITDA 0.0137 10
Total: 10
Growth impulse
Title Value Grade
Yield Revenue, % 312.97 10
Yield Ebitda, % 463.87 10
Yield EPS, % 85.85 9
Total: 9.8
More

Contained in ETF

ETFShare, %Profitability for 1 year, %Dividends, %
ERShares NextGen Entrepreneurs ETF 1.42 -5.65 0.38
AlphaMark Actively Managed Small Cap ETF 0.98902 41.15 1.74611
Syntax Stratified SmallCap ETF 0.33049 13.51 1.639
iShares Morningstar Small-Cap Value ETF 0.05016 187.77 2.50476
iShares Morningstar Small-Cap ETF 0.04554 391.25 1.60498
iShares Morningstar Small-Cap Growth ETF 0.04262 595.05 0.72598
0.48203.851.43

Similar companies

P/E & P/BVEV/Ebitda & Debt/Ebitda


Company management

Head Job title Payment Year of birth
Dr. Steven R. Miller Ph.D. Executive VP, COO & Chief Scientific Officer 809.03k 1962 (63 years)
Dr. Gary Ingenito M.D., Ph.D. Chief Medical & Regulatory Officer 751.85k 1956 (69 years)
Mr. Jeffrey Del Carmen Executive VP & Chief Commercial Officer 711.7k 1971 (54 years)
Ms. Mary Coleman VP & Head of Investor Relations N/A
Mr. Brian Elsbernd J.D. Chief Compliance Officer & Chief Legal Officer 311.42k 1964 (61 year)
Mr. Pete Curry Sr. Vice President of Sales N/A
Dr. Stanley Iyadurai M.D., Ph.D. Senior Vice President of Medical Affairs & Drug Discovery N/A
Mr. Richard John Daly M.B.A. President, CEO & Director 63.12k 1961 (64 years)
Mr. Michael W. Kalb CPA Executive VP, Treasurer & CFO N/A 1971 (54 years)
Dr. Preethi Sundaram Ph.D. Chief Strategy Officer 1976 (49 years)

About company

Address: United States, Coral Gables. FL, 355 Alhambra Circle - Open in google maps, Open in yandex maps
Website: https://www.catalystpharma.com